Coordinated signalling between different cell types of the 'normal stroma' is required during embryonic and adult development 1 . The stroma can be appropriately activated in response to extreme but normal physiological cues, such as wounding, inflammation or pregnancy 2 . The stroma can also be inappropriately activated in cancer 3, 4 . In breast tumours, stromal fibroblasts are believed to adapt and continuously co-evolve with tumour epithelial cells to foster transformation and tumour growth 5 . Fibroblasts are a principal constituent of the stroma responsible for the synthesis of growth and survival factors, angiogenic and immunological chemokines, and structural components of the ECM as well as enzymes that control its turnover 6, 7 . Despite extensive evidence for a role of the tumour stroma in carcinogenesis, relatively little is known about the signalling pathways involved in the communication between the different cellular compartments of the microenvironment that contribute to the cancer phenotype.
Alterations in the phosphoinositide 3-kinase (PI3K) pathway are associated with the activation of tumour-associated stroma 8, 9 . One of the main regulators of PI3K signalling is the phosphatase and tensin homologue (PTEN), a tumour suppressor with lipid and protein phosphatase activity 10, 11 . PTEN inactivation disrupts multiple cellular processes associated with cell polarity, cell architecture, chromosomal integrity, cell cycle progression, cell growth and stem cell self-renewal 12, 13 . Germ-line inactivation of a single allele of PTEN in both humans and mice contributes to the genesis of a variety of tumour types of epithelial origin 14 . Although tremendous progress in understanding PTEN function in tumour cells has been made since its discovery over a decade ago, relatively little is known about its potential role in the tumour stroma. Here, we show that Pten ablation in mammary stromal fibroblasts of mice results in massive remodelling of the ECM and tumour vasculature, recruitment of innate immune cells and increased malignancy of mammary epithelial tumours. Gene expression profiling of Pten-deleted stromal fibroblasts identified the activation of an Ets2-specific transcription program associated with many of these aggressive tumour phenotypes. Remarkably, the concomitant inactivation of Ets2 in the mammary stroma reversed the increased malignancy caused by Pten deficiency. These findings expand Pten's repertoire as a tumour suppressor by identifying the fibroblast as a key site from which it exerts its powerful tumour suppressive influence on the adjacent tumour epithelium.
Stromal Pten suppresses mammary epithelial tumours
To evaluate rigorously the role of Pten in the tumour microenvironment of breast cancer, we generated mice containing a mesenchymalspecific Fsp-cre transgene 15 and conditional alleles of Pten (Pten loxP ; Supplementary Fig. 1 ). Cell-type-marker analysis using a b-galactosidase Rosa26 LoxP reporter allele showed specific Fsp-cre expression in stromal fibroblasts surrounding the mammary epithelial ducts, with no expression in cytokeratin-positive epithelial cells, F4/80-positive macrophages and CD31-positive endothelial cells ( Fig. 1a and Supplementary Fig. 2a, b) . Western blot and PCR assays demonstrated efficient cre-mediated deletion of Pten loxP in stromal fibroblasts isolated from Fsp-cre;Pten loxP/loxP mammary glands ( Fig. 1b and Supplementary Fig. 3a ). Examination of mammary sections by immunohistochemistry (IHC) and immunofluorescence showed deletion of Pten loxP that was confined to stromal fibroblasts, with no collateral deletion in epithelial ducts or the adjacent myoepithelium ( Fig. 1c and Supplementary Fig. 3b, c) . Interestingly, this resulted in the expansion of the ECM, but did not lead to the transformation of the mammary epithelium ( Fig. 1c, e ).
We then examined the role of stromal Pten on mammary tumorigenesis using an established mouse model of breast cancer, MMTV-ErbB2/neu (ErbB2) 16 . To avoid possible confounding effects caused by Pten deletion in mesenchymal cells of other organs, mammary glands from Fsp-cre;Pten loxP/loxP , ErbB2;Pten loxP/loxP and ErbB2;Fspcre;Pten loxP/loxP donors were transplanted into syngeneic wild-type recipients 17 and tumour development was monitored over the course of several months. By genetically marking the stroma with the Rosa26 LoxP reporter allele, we demonstrated that both the epithelium and its associated stroma were effectively transplanted into host female mice ( Supplementary Fig. 4 ). Loss of Pten in stromal fibroblasts dramatically increased the incidence of ErbB2-driven mammary tumours ( Fig. 1d-f ). By 16 weeks post-transplantation, these lesions progressed to adenoma, carcinoma in situ and invasive carcinoma (Fig. 1g ), and by 26 weeks most females met the criteria for early removal due to excessive tumour burden ( Fig. 1f ). Histological examination showed that ErbB2-tumour cells in Pten stromal-deleted tumours retained their typical oncogene-specific morphology, with small nuclei, fine chromatin and abundant eosinophilic cytoplasm 18 . In contrast to non-deleted tumours 18, 19 , Pten stromal-deleted tumours had a significant amount of stroma surrounding and infiltrating the epithelial masses ( Fig. 1g ). PCR-based and immunohistochemical assays confirmed that tumours had intact Pten loxP alleles in the epithelial compartment ( Supplementary Fig. 5a , b and data not shown). Moreover, we used the Rosa26 loxP reporter allele to mark genetically early epithelial to mesenchymal transition events 15 and found no evidence of epithelial to mesenchymal transition in tumours that either contained or lacked Pten in stromal fibroblasts (data not shown). Thus, the analysis of the ErbB2 breast-cancer tumour model identified a potent tumour suppressor role for Pten in stromal fibroblasts of the mammary gland.
Stromal Pten controls ECM and innate immune functions
To investigate the tumour suppressive mechanism of Pten action in stromal fibroblasts, we profiled the transcriptome of mammary stromal fibroblasts isolated from Pten loxP/loxP and Fsp-cre;Pten loxP/loxP females. Details of sample collection, processing of Affymetrix oligo-arrays and expression data are available in Methods. Briefly, we implemented class comparison analyses of all probe sets on the Affymetrix mouse genome 430 2.0 array to identify genes differentially expressed between the two genetic groups. We also used an unbiased approach similar to gene set enrichment analysis 20 to identify a priori defined groups of genes that were significantly differentially expressed. The analysis of over 14,000 mouse genes identified 129 upregulated and 21 downregulated unique genes in response to Pten deletion ( Supplementary Fig. 6a , b; greater than fourfold at P , 0.001; Supplementary Tables 1 and 2 ). Reverse transcription followed by quantitative PCR (quantitative RT-PCR) assays on a subset of genes confirmed more than 85% of these expression ARTICLES changes using independent fibroblast samples ( Supplementary Fig. 6c and Supplementary Table 3 ). Fibroblast samples used to probe the oligo-arrays lacked expression of macrophage-, endothelial-and epithelial-specific genes, confirming the purity of these fibroblast preparations ( Supplementary Fig. 6d ). Functional annotation 21, 22 of Pten-responsive targets revealed a remarkable bias towards genes encoding proteins involved in ECM remodelling, wound healing and chronic inflammation 21, 22 ( Fig. 2a and Supplementary Tables 1 and 2) . Given this unexpected convergence of function, we performed a more thorough cellular and molecular analysis of Pten-deleted stroma.
Staining of consecutive mammary gland sections with haematoxylin and eosin (H&E) and Mason's trichrome stains indicated enhanced deposition of collagen in Pten-deleted stroma, which was independent of ErbB2-oncogene expression (Fig. 2b, c and Supplementary Fig. 7a ). IHC and western blot assays using collagen type-specific antibodies showed that the non-cellular material consisted mostly of type-I collagen and not the basement membrane type-IV collagen (Fig. 2b, c and Supplementary Fig. 7b , c). There was significant infiltration of F4/80-positive macrophages into stromal Pten-deleted mammary glands ( Fig. 2d, e ), and this was independent of ErbB2 expression ( Supplementary Fig. 8a ). The abundance of B and T cells did not change in response to stromal deletion of Pten (data not shown).
From these experiments, we conclude that ablation of Pten in stromal fibroblasts recapitulates two key events associated with tumour malignancy: increased ECM deposition and innate immune cell infiltration.
Stromal Pten loss activates Ets2
Along with the remarkable remodelling of the tumour microenvironment, loss of Pten in stromal fibroblasts resulted in activation of the Ras, JNK and Akt pathways. Western blot analysis using protein lysates derived from Pten-deleted stromal fibroblasts demonstrated an increase in the phospho-specific forms of Akt (Akt T308/S473 ) and JNK (JNK T183/Y185 ) ( Fig. 2f and Supplementary Fig. 8b ). Immunohistochemical assays confirmed the activation of Akt and JNK in stromal fibroblasts, and, interestingly, revealed a profound activation of these two pathways in ductal epithelial cells adjacent to the Ptendeleted stroma ( Fig. 2g and Supplementary Fig. 8b ). This analysis also showed increased levels of phospho-Erk1/2 in Pten-deleted stromal fibroblasts; however, this increase could not be detected in primary cultured fibroblasts ( Fig. 2f , g), presumably owing to the constitutive Pten-independent activation of Erk1/2 by serum-stimulation 23 . Among the many expression changes observed in Pten-deleted stromal fibroblasts we noted that there was a significant increase of Ets2 messenger RNA (mRNA) levels (2.8-fold, P , 0.001). This induction is notable because the Ets2 transcription factor is known to be transcriptionally induced by MAPK 24, 25 activation and its function to be post-translationally enhanced by the Akt-and JNKmediated phosphorylation of its pointed domain at threonine 72 (Ets2 T72 ) 23, 26 . We confirmed the higher levels of Ets2 mRNA and protein in Pten-deleted fibroblasts (approximately threefold, P , 0.001; Supplementary Fig. 9a, b ) and, consistent with the activation of Akt and JNK in these mammary glands, there was a marked increase of phospho-Ets2 T72 in stromal fibroblasts and adjacent epithelial ducts ( Fig. 2h , i). Loss of Pten in stromal fibroblasts resulted in the induction of several genes involved in ECM remodelling and macrophage recruitment, two of which, Mmp9 and Ccl3, are known to be direct transcriptional targets of Ets2 27, 28 ( Supplementary Figs 6c  and 9c ). The increase of Mmp9 expression appears to be of pathological relevance because in situ zymography 29 showed robust Mmp9 activity in tumour samples ( Supplementary Fig. 9d ). Chromatin immunoprecipitation (ChIP) assays showed an increase in the loading of Ets2 onto the Mmp9 and Ccl3 promoters in Pten-deleted mammary fibroblasts ( Supplementary Fig. 9e ), suggesting a direct role for Ets2 in the transcriptional regulation of these two target genes in vivo. Together, these data illustrate the extensive molecular reprogramming that takes place in the tumour and its microenvironment in response to ablation of Pten in stromal fibroblasts.
Stromal Ets2 promotes mammary tumorigenesis
To determine whether Ets2 promotes a microenvironment conducive to tumour growth, we analysed the consequences of ablating a conditional allele of Ets2 (Ets2 loxP ) 30 in mammary stromal fibroblasts of a well-characterized mouse model of breast cancer, MMTV-PyMT (PyMT) 31 . The PyMT oncogene initiates the rapid onset and progression of mammary tumours and thus represents an appropriate model for evaluating any potential delay that loss of Ets2 might have on tumorigenesis. The efficient Fsp-cre-mediated ablation of Ets2 in stromal fibroblasts was facilitated by using mice carrying conventional and conditional knockout alleles of Ets2 (DNA binding domain Ets2 db/LoxP ) 32 ( Fig. 3a and Supplementary Fig. 10a, b ). Ablation of Ets2 in these cells had no detectable physiological consequence on the development of mammary glands, either during puberty or pregnancy (M.C.O., unpublished observations). The evaluation of PyMT;Fsp-cre;Ets2 db/loxP and control PyMT;Ets2 db/loxP mice over a period of three months showed that ablation of Ets2 in mammary fibroblasts significantly reduced the tumour load ( Fig. 3b ) and slowed progression to adenoma and early carcinoma ( Fig. 3c ). Quantitative RT-PCR showed high levels of Mmp9 expression in tumour-associated fibroblasts containing Ets2 and low levels in Ets2-deleted fibroblasts (Fig. 3e ). Because Mmp9 activity is known to mediate the release of matrix-bound VEGF-A to its active isoforms, including VEGF 164 (ref. 33) , we visualized the spatial distribution of VEGF 164 and Mmp9 activity by immunofluorescence. These assays showed that the accumulation of VEGF 164 , which was particularly acute within collagen-1A-rich stromal locations overlapping Mmp9 activity, was significantly decreased in stromal-deleted Ets2 tumours ( Fig. 3d, f) . Given that VEGF 164 is a specific ligand for VEGF Receptor 2 (VEGFR2; FLK-1; KDR), one of the most potent mediators of VEGF-induced endothelial signalling and angiogenesis 34 , we also evaluated VEGFR2 status by immunostaining tumour sections with antibodies specific for CD31 and the phospho-activated form of the murine VEGF receptor (VEGFR2 Y1173 ) 35 . This analysis revealed a fourfold decrease in the number of CD31/VEGFR2 Y1173 doublepositive cells in Ets2-deleted versus non-deleted tumour samples ( Fig. 3f, g) . Together, these data show that loss of Ets2 in stromal fibroblasts results in decreased Mmp9 activity in the tumour ECM and reduced VEGFR2 Y1173 activation in the tumour vasculature.
Ets2 is a key component of the stromal Pten axis We then entertained the hypothesis that Ets2 may be contributing to the remodelling of the tumour microenvironment caused by stromal deletion of Pten. To test this possibility directly, we compared tumour incidence in Pten loxP/loxP , Fsp-cre;Pten loxP/loxP and Fsp-cre; Pten loxP/loxP ;Ets2 db/loxP mammary glands that were orthotopically injected with an established ErbB2-initiated mammary tumour cell line (NT2.5) 36 . This orthotopic model recapitulated the consequences of deleting Pten in the mammary stroma that were observed in the genetically engineered ErbB2-mouse model described earlier in this study. Indeed, tumour incidence and tumour load in injected Fsp-cre;Pten loxP/loxP females was markedly higher than in control Pten loxP/loxP females (Fig. 4a, b ). Importantly, mammary glands doubly deleted for stromal Pten and Ets2 had fewer and smaller tumours than glands deleted for Pten only. These mammary tumours had decreased numbers of macrophages and recruitment of new vasculature ( Fig. 4c-f ). Loss of Pten and Ets2, however, failed to reduce the tumour load and collagen deposition fully to control levels ( Fig. 4b and Supplementary Fig. 11a, b ), suggesting that additional effectors must contribute towards Pten's tumour suppressor functions. From these data, we conclude that Ets2 is a major component of the Pten tumour-suppressive axis that acts in the stromal fibroblast compartment of mammary glands.
Human breast tumour stroma contains a Pten signature To determine the relevance of these findings to human breast cancer, we compared the mouse stromal fibroblast Pten expression signature to the expression signatures derived from laser-captured tumour stroma (49 samples) and adjacent normal stroma (52 samples) in patients with breast cancer 37 . This analysis identified 137 human orthologues from the 150 differentially expressed mouse genes detected by the Affymetrix oligo-arrays shown in Supplementary  Fig. 6a , b. Of these 137 orthologues, 129 genes were represented in the expression platform used (Agilent) for the analysis of human patient stroma samples 37 . Only 70 of these 129 genes had highly variable gene expression across all human stromal samples (a variance cutoff of greater than 0.5). The heat map generated for the human stroma data set showed that this 70 gene subset derived from the mouse Pten-signature was sufficient to distinguish normal from tumour stroma in all patients ( Fig. 5a ; P 5 8 3 10 25 as determined by a permutation test). Principal component analysis also discriminated normal from tumour stroma perfectly (P , 1 3 10 210 ; Supplementary Fig. 12 ). Interestingly, 12 of the 70 human orthologues identified by the Pten-signature ( Fig. 5a : gene names highlighted in red; Supplementary Fig. 13 ) were previously shown to be differentially expressed in the tumour stroma of patients with breast cancer and to be associated with recurrence 37 (Fig. 5b ; P 5 2.5 3 10 28 , Fisher's exact analysis). These analyses suggest that the fibroblast Pten-expression signature identified by our stromal mouse model represents a significant subset of the total gene signature expressed in the stroma of human breast cancer. We interpret these results to mean that a portion of the transcriptome regulated by Pten in mammary stromal fibroblasts is dysregulated in the tumour stroma of patients with breast cancer. We also evaluated the relevance of the Pten-Ets2 relationship in human cancer by immunohistochemical staining of breast-cancer tissue microarrays (TMAs) with antibodies specific for Pten, P-Ets2 T72 and P-Akt S473 (Fig. 5c ). From the analysis of 99 patient samples with invasive carcinoma, PTEN expression was scored as absent or low in approximately 50% of samples. Importantly, PTEN staining in the TMAs was negatively correlated with P-AKT S473 and nuclear P-ETS2 T72 , whereas P-AKT S473 and nuclear P-ETS2 T72 showed a positive association (Fig. 5d ). These results suggest that activation of P-ETS2 T72 in human breast-cancer stroma is a pathological event that is favoured by a reduction in PTEN expression.
Discussion
Histopathology and molecular studies suggest that malignant tumours consist of a complex cellular system that is dependent on reciprocal signalling between tumour cells and the adjacent stroma. However, the signalling pathways that mediate the communication between the various cell types in the tumour remain virtually unknown. We recently developed a mesenchymal-specific cre mouse 15 and used it here to examine the consequences of inactivating Pten in mammary stromal fibroblasts. Using this system we show, for the first time to our knowledge, that Pten in stromal fibroblasts has a critical role in the suppression of epithelial mammary tumours that is, in part, mediated through an Ets2-regulated transcriptional program.
The tumour suppressor functions of PTEN have been extensively studied in the tumour cell [38] [39] [40] . We show here that genetic ablation of Pten in mammary stromal fibroblasts of mice alters the expression profile of these cells to increase ECM, chemokine and cytokine production in the tumour microenvironment. As a result, Pten stromal-deleted tumours exhibit high levels of collagen, macrophage recruitment and vascular networks, which together favour the initiation and progression of mammary epithelial tumours. Remarkably, side-by-side evaluation of histopathology by independent pathologists could not distinguish tumours between Pten stromal-deleted mice and human patients with breast cancer, highlighting the importance of modelling stromal cell compartments of the tumour microenvironment. The mechanism by which Pten in the stroma likely exerts its tumour suppressor role is through the control of multiple signalling pathways, including components of the Ras, Akt and JNK networks, which together culminate in the regulation of Ets2 transcriptional activity. The fact that loss of Ets2 in mammary stromal fibroblasts diminished the oncogenic consequences of deleting Pten in these cells underscores the importance of the stromal Pten-Ets2 axis in stromal fibroblasts during tumour suppression. These observations are consistent with previous work from Oshima and colleagues that showed a critical cell non-autonomous role for Ets2 in the growth of mammary tumours in mice 41 and with the identification of Ets2 activation as a key event associated with breast cancer in human patients having poor prognosis [42] [43] [44] . The relevance of this mouse Pten-Ets2 tumour suppressor axis to breast cancer is underlined by the high correspondence between the mouse and human stromal expression signatures. The observation that the dire consequences of targeting this Ets2-driven stromal program are tumour-specific, sparing normal mammary development, emphasizes the potential use of stromalspecific strategies for therapeutic intervention in human breast cancer.
In summary, this work identifies Pten-Ets2 as a key regulatory axis in stromal fibroblasts that suppresses mammary epithelial tumours by profoundly attenuating some of the most malignant characteristics of the tumour microenvironment. This novel function of Pten may be relevant in the suppression of epithelial tumours of other organs, but may also extend beyond cancer, to conditions where the microenvironment may impact disease manifestation, such as in autoimmune syndromes 45 , lung fibrosis 46 and neurodegeneration 47 . Interestingly, the stromal Pten expression signature identified here includes genes that have been causally linked to ECM deposition and inflammation in rheumatoid arthritis, lung fibrosis and neurodegeneration ( Supplementary Tables 1 and 2) . These data offer a molecular basis for how altered Pten signalling in the tumour stroma may elicit broad responses in a variety of cells in the tumour microenvironment that contribute to disease manifestation.
METHODS SUMMARY
Transgenic mice. Generation of Fsp-cre mice has been described 15 . Pten loxP mice were created following the strategy described in Supplementary Fig. 1 . Ets2 loxP mice were generated by standard techniques 30 . Animals were maintained and killed following institutional guidelines. Tenth-generation congenic (N10) FVB/ N animals were used for transplantation and orthotopic injection studies. Tissue processing, histology. Tissues were either embedded in OCT or fixed (4% paraformaldehyde or formalin) and embedded in paraffin. Frozen sections were used for X-gal staining as previously described 15 . IHC on tissue microarray sections from 99 patients with breast carcinoma was scored using Allred score's system 48 . Isolation of primary mammary fibroblasts. Primary mammary fibroblasts were purified following the protocol published previously with minor modifications 49 . Mammary glands were dissected from 8-week-old female mice, minced and digested with collagenase (0.15% Collagenase I, 160 U ml 21 hyaluonidase, 1 mg ml 21 hydrocortisone and 10 mg ml 21 insulin with penicillin and streptomycin) in a 5% CO 2 incubator overnight at 37 uC. Collagenase was neutralized with 10% FBS-DMEM medium. Digested tissue was resuspended in medium and subjected to gravity for 12-15 min. Pellets were washed three times to collect epithelial organoids, and supernatants were subjected four more times to gravity sedimentation and then cultured. RNA and microarray analysis. RNA was harvested with Trizol according to the manufacturer's instructions (Invitrogen). RNA quality and concentration were assessed with Bioanalyser and Nanodrop RNA 6000 nano-assays. RNA samples were hybridized to Affymetrix GeneChip Mouse genome 430 2.0 platform at the Microarray Shared Resource Facility, Ohio State University Comprehensive Cancer Center. The microarray data were deposited with Gene Expression Omnibus (GEO) and can be viewed at http://www.ncbi.nlm.nih.gov/geo/query/ acc.cgi?token5zhmbrcoqaacyite&acc5GSE16073. 
METHODS
Transgenic mice. Animals were housed according to federal and University Laboratory Animal Resources at Ohio State University regulations. Fsp-cre: the generation of the Fsp-cre mouse line has been previously described 15 .
Ets2 loxP : the Ets2 conditional transgenic mouse line was generated such that the Ets2 pointed domain is 'floxed' 28 . The pointed domain is encoded by exons 3-5 and important for the protein-protein interaction and signal transduction. Ets2 db : the Ets2 db mouse was a gift from R. G. Oshima 32 .
Pten loxP : the Pten loxP mice were generated in our laboratory. LoxP sites were introduced into two HpaI sites within introns 3 and 5 of the Pten gene, respectively, to flank exons 4 and 5. Exon 5 encodes the lipid phosphatase domain. Tissue-specific expression of cre will excise exons 4 and 5, generating a loss-offunction Pten D allele ( Supplementary Fig. 1 ). Rosa-LacZ: the generation of the conditional Rosa-LacZ mouse line has been previously described 50 . A list of PCR primers can be found in Supplementary  Table 3 . Mammary tissue transplantation. Transplant procedure was based on a previously published method 17 . The day before surgery, recipient mice were anaesthetized with isofluorane (Abbott Laboratories) and a square area along the scapular region was shaved (roughly 25 mm 3 25 mm). At the time of surgery, inguinal and groin mammary tissue (approximately 5 mm 3 5 mm in size) was removed from 8-to 9-week-old donor females and placed subcutaneously into the scapular region of wild-type hosts (littermates or FVB/N purchased from Taconic) through two 5-to 10-mm incisions on the left and right side under aseptic conditions. Only tissue from the abdominal (#4 and #9) and groin (#5 and #10) mammary glands was used for transplant after the lymph nodes were removed. The small incisions were closed using a 9-mm wound clip. Animals were monitored twice a week until tumour onset. Mice were killed either at specific time points, when the tumour was about 2 cm in size, or it presented a health problem to the animal such as exterior ulceration at the site of the tumour.
Orthotopic mammary gland injection. The neu-expressing mouse mammary carcinoma cell line NT2.5 was provided by P. T. Kaumaya and was maintained as described 36 . Eight-week-old female mice of each genotype were anaesthetized and injected with 5 3 10 5 NT2.5 cells at both inguinal mammary glands. Tumour initiation was monitored by palpating twice a week. All the mice were killed three weeks after injection. Tumour volume was calculated by the formula V 5 K 3 length 3 (width) 2 .
Tissue processing and X-gal staining. Large individual tumours (typically ,1-on the heat map, and to identify only those genes that had highly variable gene expression across all samples, a variance cutoff of .0.5 was used to generate a subset of 70 genes. The heat map (Fig. 5a ) shows the ability of these 70 genes to separate the normal and tumour stroma samples based solely on their gene expression profiles. This partitioning is highly significant (P 5 3.9 3 10 215 ), as determined by Wilcoxon's test on the average expression of Pten null-signature in all samples. Interestingly, comparison of 137 human orthologues of the Pten null list with the 163 genes associated with recurrence in tumour stroma from the McGill study showed that there are 12 genes (highlighted in red; Fig. 5a ) present on both gene lists. This overlap is again highly significant (P 5 2.5 3 10 28 ; Fisher's exact analysis). TMA. TMA slides containing paraffin-embedded breast carcinoma tissues were processed at the Pathology Core Facility and Tissue Archives Human Tissue Resource Network at Ohio State University. IHC on these slides was performed with phospho-Ets2 T72 (1:25, M.C.O. laboratory), Pten (1:100, Cell Signaling) and phospho-Akt S473 (1:50, Cell Signaling) following standard procedures. Level of PTEN and phospho-ETS2 and phospho-AKT expression in stromal cells were scored with Allred score method 48 . Statistical analysis. The number of animals and experiments are indicated in the figures. All the statistical tests were two-sided. The Wilcoxon rank test was used for some of the statistical analyses when the outcome variables were skewed and could not be transformed to achieve normality (Figs 1f and 2c , e, i). General linear models (analysis of variance) were used to study differences in continuous outcome variables among groups. Ad hoc pairwise comparisons were performed if the overall test was significant ( Fig. 4b, d , f and Supplementary Figs 9c and  11b ). Fisher's exact test was used to compare counts in Fig. 1e because low counts (below 5) were observed in one of the groups. Fisher's exact test was also used to compare gene overlap in Fig. 5b . Multiplicity adjustment methods (Bonferroni method) were used when multiple pairwise comparisons were performed. A two-sample (unpaired) Student's t-test was used for tumour load and the fluorescent microscopy images of VEGF 164 , CD31 and pVEGFR Y1173 staining in Fig. 3b , e, f and Supplementary Fig. 9a , e. For human TMA, a Pearson correlation was used to evaluate the association of Allred scores between PTEN/P-ETS2 T72 , PTEN/P-AKT S473 and P-ETS2 T72 /P-AKT S473 .
We show the expression data comparing normal and tumour stroma in Fig. 5a as a heat map because it highlights the 'direction' of the change in expression. Moreover, a permutation test strategy was used to study whether the 70-gene subset of the mouse Pten signature discriminated between human tumour and normal stroma samples 54 (Fig. 5a) . A total of 100,000 random permuted samples was used to compute the empirical P value of the 70-gene signature. A Wilcoxon rank sum value for each random 70-gene permutation was computed from the average log expression difference (between normal and tumour stroma) of the 70 genes. For computing the average log expression difference of the mouse Pten 70-gene signature, we assigned negative values to the 13 downregulated genes. The empirical P value obtained using this method (8 3 10 25 ) represents the proportion of random permuted samples that had a Wilcoxon rank sum value larger than the Wilcoxon rank sum value of the Pten 70-gene unpermuted signature. In addition, principal component analysis was used to explore whether the Pten 70-gene signature discriminated normal versus tumour stroma; this principal component analysis, like the heatmap presented in Fig. 5a , showed perfect separation of normal and tumour samples (data not shown), with the first component being sufficient for this separation. A Wilcoxon rank sum test yielded a P value of less than 1 3 10 210 .
